ClinicalTrials.gg
CompletedNCT00434577Updated Mar 15, 2019Results posted

Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects

A Phase 2 interventional study of Herpes Zoster vaccine GSK1437173A Low Dose and Herpes Zoster vaccine GSK1437173A Medium Dose in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 11 sites in 4 countries. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-15.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
715
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Herpes Zoster by GlaxoSmithKline — 3 open to participants now, 5 under way, 1 of them phase 3. Herpes Zoster · GlaxoSmithKline.

Enrollment
15th of 37
715 · median 450
Started
2007
with 2 others
Phase 2
8 of 44
1 open now
Registered
2nd of 44
by date

Among the 44 studies in Herpes Zoster by GlaxoSmithKline, this one is the 15th largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2007, is one of 8 in phase 2, and was the 2nd registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

3 of the 44 studies in Herpes Zoster by GlaxoSmithKline are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Herpes Zoster by GlaxoSmithKline, or all of them as a file.
02

Study summary

Based on the results of a previous clinical PhaseI/II study, GSK1437173A is the lead GSK candidate Herpes Zoster (HZ) vaccine to prevent episodes of HZ (shingles). This phase II study will be subdivided into a primary study (108494) and three extension studies (108516, 108518 \& 108520), consisting of one additional visit each at months 12, 24 and 36, respectively, from the first visit of the Zoster-003 primary study onwards. The aim of the primary 108494 study is to evaluate the immunogenicity \& safety of different dosages of the GSK1437173A vaccine in healthy elderly population. The study population will be stratified by age. The primary objective of this trial is to select the best dosage of GSK1437173A. The aim of the extension studies is to evaluate the persistence of the immune response induced by the candidate HZ vaccine during a long term period.

No new subjects will be enrolled during the extension phases of the study.

Read the detailed description

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

03

Conditions studied

  • Herpes Zoster

Keywords

  • GSK Biologicals
  • Herpes Zoster (HZ)
  • Vaccine
  • Varicella Zoster Virus (VZV)
  • Shingles
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who the investigator believes that they can and will comply with the requirements of the protocol.
  • A male or female aged 60 years or older at the time of the first vaccination.
  • Written obtained from the subject

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first injection with study vaccine, or planned use during the study period.
  • Chronic administration (defined as more than 14 days) of or other immune-modifying drugs during the study period, except inhaled and topical are allowed.
  • Administration or planned administration of a vaccine not foreseen by the study protocol within 2 weeks of the first study vaccine injection, with the exception of the influenza vaccine, which can be administered 1 week preceding or 1 month after the first study vaccine injection.
  • Previous vaccination against HZ.
  • History of herpes zoster (Shingles).
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
  • Acute disease at the time of enrolment.
  • Acute or chronic, pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by subject's medical history or physical examination as assessed by the investigator.
  • Administration of immunoglobulins and/or any blood products within the 3 months preceding the first injection of study vaccine or planned administration during the study period.
  • History of or current drug and/or alcohol abuse.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
715 participants (actual)

Study arms

  • Experimental
    GSK1437173A _LD Group

    Healthy male or female subjects aged 60 years or older, who received 2 doses of herpes zoster subunit vaccine (GSK1437173A) low dose (LD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by intramuscular injection (IM) in the upper deltoid site of the left arm.

    Biological: Herpes Zoster vaccine GSK1437173A Low Dose

  • Experimental
    GSK1437173A _MD Group

    Healthy male or female subjects aged 60 years or older, who received 2 doses of herpes zoster subunit vaccine (GSK1437173A) medium dose (MD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.

    Biological: Herpes Zoster vaccine GSK1437173A Medium Dose

  • Experimental
    GSK1437173A _HD Group

    Healthy male or female subjects aged 60 years or older, who received 2 doses of herpes zoster subunit vaccine (GSK1437173A) high dose (HD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.

    Biological: Herpes Zoster vaccine GSK1437173A High Dose

  • Placebo comparator
    Placebo + GSK1437173A _HD Group

    Healthy male or female subjects aged 60 years or older, who received a 1st dose of saline solution and a 2nd dose of GSK1437173A high dose (HD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.

    Biological: Herpes Zoster vaccine GSK1437173A High Dose · Biological: Placebo

  • Active comparator
    GSK1437173A_MODIFIED GROUP

    Healthy male or female subjects aged 60 years or older, who received 2 doses of GSK1437173A modified formulation vaccine reconstituted with saline solution, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.

    Biological: Herpes Zoster vaccine GSK1437173A Modified

Interventions

  • BiologicalHerpes Zoster vaccine GSK1437173A Low Dose

    Single or two-dose intramuscular injection.

  • BiologicalHerpes Zoster vaccine GSK1437173A Medium Dose

    Single or two-dose intramuscular injection.

  • BiologicalHerpes Zoster vaccine GSK1437173A High Dose

    Single or two-dose intramuscular injection.

  • BiologicalHerpes Zoster vaccine GSK1437173A Modified

    Single or two-dose intramuscular injection.

  • BiologicalPlacebo

    Single intramuscular injection

06

What researchers measure

Primary outcomes

  1. Frequency of Glycoprotein E (gE)-Specific Cluster of Differentiation (CD4) T-cells Expressing at Least Two Different Activation Markers

    Among the activation markers expressed were interleukin-2 \[IL-2\] and/or interferon-gamma \[IFN-γ\] and/or tumour necrosis factor-alpha \[TNF-α\] and/or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS) in subjects aged 70 or higher (≥).

    Time frame: One month after the second vaccination (Month 3)

  2. Frequency Odds Ratio of gE-specific CD4 T-cells Expressing at Least Two Different Activation Markers

    Among the activation markers expressed were interleukin-2 \[IL-2\] and/or interferon-gamma \[IFN-γ\] and/or tumour necrosis factor-alpha \[TNF-α\] and/or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS) in subjects ≥ 70 years old. The odds-ratios are calculated using the the frequency of CD4 secreting cytokines, upon in vitro stimulation with the specific antigen, at the numerator and the frequency of the CD4 secreting cytokines with the medium only (background level) at the denominator. The odds-ratios represent the fold-change in the specific response compared to the background level.

    Time frame: One month after the second vaccination (Month 3)

  3. Frequency of gE-specific CD4 T-cells Expressing at Least Two Different Activation Markers

    Among the activation markers expressed were interleukin-2 \[IL-2\] and/or interferon-gamma \[IFN-γ\] and/or tumour necrosis factor-alpha \[TNF-α\] and/or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS) in subjects ≥ 70 years old.

    Time frame: One month after the second vaccination (Month 3)

Secondary outcomes

  1. Frequency of gE-specific CD4 T-cells Expressing at Least Two Different Activation Markers

    Among the activation markers expressed were interleukin-2 \[IL-2\] and/or interferon-gamma \[IFN-γ\] and/or tumour necrosis factor-alpha \[TNF-α\] and/or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS) in subjects 60 to 69 years (60-69y) and ≥ 70 years (+70y) old.

    Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)

  2. Frequency of gE-specific CD4 T-cells Expressing IFN-γ and at Least Another Activation Marker

    Among other activation markers expressed were interleukin-2 \[IL-2\] or tumour necrosis factor-alpha \[TNF-α\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).

    Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)

  3. Frequency of gE-specific CD4 T-cells Expressing IL-2 and at Least Another Activation Marker

    Among other activation markers expressed were interferon-gamma \[IFN-γ\] or tumour necrosis factor-alpha \[TNF-α\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).

    Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)

  4. Frequency of gE-specific CD4 T-cells Expressing TNF-α and at Least Another Activation Marker

    Among other activation markers expressed were interleukin-2 \[IL-2\] or interferon-gamma \[IFN-γ\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).

    Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)

  5. Frequency of gE-specific CD4 T-cells Expressing CD40L and at Least Another Activation Marker

    Among other activation markers expressed were interleukin-2 \[IL-2\] or interferon-gamma \[IFN-γ\] or tumour necrosis factor-alpha \[TNF-α\] . Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).

    Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)

  6. Frequency of gE-specific CD8 T-cells Expressing at Least Two Different Activation Markers

    Among the activation markers expressed were interleukin-2 \[IL-2\] and/or interferon-gamma \[IFN-γ\] and/or tumour necrosis factor-alpha \[TNF-α\] and/or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).

    Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)

  7. Frequency of gE-specific CD8 T-cells Expressing IFN-γ and at Least Another Activation Marker

    Among other activation markers expressed were interleukin-2 \[IL-2\] or tumour necrosis factor-alpha \[TNF-α\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).

    Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)

  8. Frequency of gE-specific CD8 T-cells Expressing IL-2 and at Least Another Activation Marker

    Among other activation markers expressed were interferon-gamma \[IFN-γ\] or tumour necrosis factor-alpha \[TNF-α\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).

    Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)

  9. Frequency of gE-specific CD8 T-cells Expressing TNF-α and at Least Another Activation Marker

    Among other activation markers expressed were interleukin-2 \[IL-2\] or interferon-gamma \[IFN-γ\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).

    Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)

  10. Frequency of gE-specific CD8 T-cells Expressing CD40L and at Least Another Activation Marker

    Among other activation markers expressed were interleukin-2 \[IL-2\] or interferon-gamma \[IFN-γ\] or tumour necrosis factor-alpha \[TNF-α\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).

    Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)

  11. Anti-gE Specific Antibody Concentrations

    Concentrations were presented as geometric mean concentrations (GMCs) and expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).

    Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)

  12. Anti-varicella Zoster Virus (VZV) Specific Antibody Concentrations

    Concentrations were presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL), as assessed by ELISA.

    Time frame: At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)

  13. Frequency of gE-specific CD4/CD8 T-cells Expressing at Least Two Different Activation Markers

    Among the activation markers expressed were interleukin-2 \[IL-2\] and/or interferon-gamma \[IFN-γ\] and/or tumour necrosis factor-alpha \[TNF-α\] and/or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS). Month 12, 24 and 36 CMI analyses on CD8+ T cells were not performed as no detectable CD8 T+ cell response was measured to any of the vaccine formulations in the primary (108494) study.

    Time frame: At Months 12, 24 and 36

  14. Frequency of gE-specific CD4/CD8 T-cells Expressing IFN-γ and at Least Another Activation Marker

    Among other activation markers expressed were interleukin-2 \[IL-2\] or tumour necrosis factor-alpha \[TNF-α\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS). Month 12, 24 and 36 CMI analyses on CD8+ T cells were not performed as no detectable CD8 T+ cell response was measured to any of the vaccine formulations in the primary (108494) study.

    Time frame: At Months 12, 24 and 36

  15. Frequency of gE-specific CD4/CD8 T-cells Expressing IL-2 and at Least Another Activation Marker

    Among other activation markers expressed were interferon-gamma \[IFN-γ\] or tumour necrosis factor-alpha \[TNF-α\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS). Month 12, 24 and 36 CMI analyses on CD8+ T cells were not performed as no detectable CD8 T+ cell response was measured to any of the vaccine formulations in the primary (108494) study.

    Time frame: At Months 12, 24 and 36

  16. Frequency of gE-specific CD4/CD8 T-cells Expressing TNFα and at Least Another Activation Marker

    Among other activation markers expressed were interleukin-2 \[IL-2\] or interferon-gamma \[IFN-γ\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS). Month 12, 24 and 36 CMI analyses on CD8+ T cells were not performed as no detectable CD8 T+ cell response was measured to any of the vaccine formulations in the primary (108494) study.

    Time frame: At Month 12, 24 and 36

  17. Frequency of gE-specific CD4/CD8 T-cells Expressing CD40L and at Least Another Activation Marker

    Among other activation markers expressed were interleukin-2 \[IL-2\] or interferon-gamma \[IFN-γ\] or tumour necrosis factor-alpha \[TNF-α\] . Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS). Month 12, 24 and 36 CMI analyses on CD8+ T cells were not performed as no detectable CD8 T+ cell response was measured to any of the vaccine formulations in the primary (108494) study.

    Time frame: At Month 12, 24 and 36

  18. Anti-gE Specific Antibody Concentrations

    Concentrations were presented as geometric mean concentrations (GMCs) and expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).

    Time frame: At Months 12, 24 and 36

  19. Anti-varicella Zoster Virus (VZV) Specific Antibody Concentrations

    Concentrations were presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL).

    Time frame: At Months 12, 24 and 36

  20. Frequency of VZV-specific Memory B-cells in a Subset of Subjects

    Memory B cells specific to the gE antigen, as assessed by the enzyme-linked immunosorbent spot (ELISPOT) method, were expressed as a frequency of the specific memory B-cells per million memory B-cells. Results were tabulated for subjects aged 70 years and older.

    Time frame: At pre-vaccination (Day 0) and at Month 3

  21. Number of Subjects With Different Biochemical and Haematological Levels

    Among biochemical and haematological parameters assessed were albumin \[ALB\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], basophils \[BAS\], calcium \[CAL\], eosinophils \[EOS\], fibrinogen \[FIB\], haematocrit \[HEM\], hemoglobin \[Hgb\], leucocytes \[LEU\], lymphocytes \[LYM\], lactate dehydrogenate \[LDH\], monocytes \[MON\], neutrophils \[NEU\], partial thromboplastin time \[PTPT\], platelets \[PLA\], pro thrombin time \[PTT\], red blood cells \[RBC\], serum creatinine \[SCREA\], total protein \[TP\]. Levels of haematological/biochemical parameters assessed in terms of normal laboratory values were - unknown, below, within and above.

    Time frame: At Day 0, Month 2 and Month 3

  22. Number of German Subjects With Different Biochemical and Haematological Levels

    Among biochemical and haematological parameters assessed were albumin \[ALB\], calcium \[CAL\], fibrinogen \[FIB\], lactate dehydrogenase \[LDH\], partial thrombo-plastin time \[PTPT\], pro thrombin time \[PTT\], total protein \[TP\]. Levels of haematological/biochemical parameters assessed in terms of normal laboratory values were - below, within, above and missing, as compared to the pre-vaccination status (below, within, above or missing). Values for electrophoresis (globulins and albumin/globulin ratio) were not displayed.

    Time frame: At one week post-vaccination 1 (Month 0)

  23. Number of German Subjects With Different Biochemical and Haematological Levels

    Among biochemical and haematological parameters assessed were albumin \[ALB\], calcium \[CAL\], fibrinogen \[FIB\], lactate dehydrogenase \[LDH\], partial thrombo-plastin time \[PTPT\], pro thrombin time \[PTT\], total protein \[TP\]. Levels of haematological/biochemical parameters assessed in terms of normal laboratory values were - below, within, above and missing, as compared to the pre-vaccination status (below, within, above or missing). Values for electrophoresis (globulins and albumin/globulin ratio) were not displayed.

    Time frame: At one week post-vaccination 2 (Month 2)

  24. Number of Subjects With Any and Grade 3 Solicited Local Symptoms

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

    Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses

  25. Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

    Assessed solicited general symptoms were arthralgia, fatigue, fever \[defined as oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)\], headache and myalgia. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

    Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses

  26. Number of Subjects With Occurrence of Clinically Diagnosed Herpes Zoster (HZ) Episodes

    Clinically diagnosed episodes included rash that was assessed by hives, idiopathic thrombocytopenic purpura, petechiae.

    Time frame: From Month 0 to Month 3

  27. Number of Subjects With Occurrence of Clinically Diagnosed HZ Episodes

    Clinically diagnosed episodes included rash that was assessed by hives, idiopathic thrombocytopenic purpura, petechiae.

    Time frame: From Month 3 up to Month 36

  28. Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

    Time frame: During the 30-day (Days 0-29) post-vaccination period

  29. Number of Subjects With Serious Adverse Events (SAEs)

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: From Month 0 to Month 3

  30. Number of Subjects With Serious Adverse Events (SAEs)

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: From Month 3 to Month 12

07

Results

Posted Jan 8, 2019

Participant flow

Months 0-3
Participant flow — Months 0-3
MilestoneGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Started16416616516554
Completed16116416116451
Not completed32413
Withdrew: Serious adverse event00100
Withdrew: Adverse event01100
Withdrew: Lost to follow-up00002
Withdrew: Protocol violation10100
Withdrew: Withdrawal by subject21111
Month 12
Participant flow — Month 12
MilestoneGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Started15615915916150
Completed15615915916150
Not completed00000
Month 24
Participant flow — Month 24
MilestoneGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Started15015515415749
Completed15015515415749
Not completed00000
Month 36
Participant flow — Month 36
MilestoneGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Started14714715015547
Completed14714715015547
Not completed00000

Outcome measures

PrimaryFrequency of Glycoprotein E (gE)-Specific Cluster of Differentiation (CD4) T-cells Expressing at Least Two Different Activation Markers

Among the activation markers expressed were interleukin-2 \[IL-2\] and/or interferon-gamma \[IFN-γ\] and/or tumour necrosis factor-alpha \[TNF-α\] and/or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS) in subjects aged 70 or higher (≥).

Time frame:
One month after the second vaccination (Month 3)
Reported as:
Median · T-cells/million cells
Frequency of Glycoprotein E (gE)-Specific Cluster of Differentiation (CD4) T-cells Expressing at Least Two Different Activation Markers
T-cells/million cellsGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Frequency of Glycoprotein E (gE)-Specific Cluster of Differentiation (CD4) T-cells Expressing at Least Two Different Activation Markers1801.23 (907.17 to 2930.71)1722.83 (1172.96 to 3229.73)1778.48 (1154.88 to 3407.91)491.03 (320.65 to 768.17)388.49 (208.57 to 610.66)
PrimaryFrequency Odds Ratio of gE-specific CD4 T-cells Expressing at Least Two Different Activation Markers

Among the activation markers expressed were interleukin-2 \[IL-2\] and/or interferon-gamma \[IFN-γ\] and/or tumour necrosis factor-alpha \[TNF-α\] and/or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS) in subjects ≥ 70 years old. The odds-ratios are calculated using the the frequency of CD4 secreting cytokines, upon in vitro stimulation with the specific antigen, at the numerator and the frequency of the CD4 secreting cytokines with the medium only (background level) at the denominator. The odds-ratios represent the fold-change in the specific response compared to the background level.

Time frame:
One month after the second vaccination (Month 3)
Reported as:
Mean · Fold Change
Frequency Odds Ratio of gE-specific CD4 T-cells Expressing at Least Two Different Activation Markers
Fold ChangeGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Frequency Odds Ratio of gE-specific CD4 T-cells Expressing at Least Two Different Activation Markers12.83 ± 13.1315.00 ± 15.8621.53 ± 71.965.92 ± 9.564.05 ± 3.20
PrimaryFrequency of gE-specific CD4 T-cells Expressing at Least Two Different Activation Markers

Among the activation markers expressed were interleukin-2 \[IL-2\] and/or interferon-gamma \[IFN-γ\] and/or tumour necrosis factor-alpha \[TNF-α\] and/or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS) in subjects ≥ 70 years old.

Time frame:
One month after the second vaccination (Month 3)
Reported as:
Mean · T-cells/million cells
Frequency of gE-specific CD4 T-cells Expressing at Least Two Different Activation Markers
T-cells/million cellsGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Frequency of gE-specific CD4 T-cells Expressing at Least Two Different Activation Markers2269.84 ± 1934.552441.95 ± 2055.112449.90 ± 1808.00681.73 ± 665.17512.55 ± 463.35
SecondaryFrequency of gE-specific CD4 T-cells Expressing at Least Two Different Activation Markers

Among the activation markers expressed were interleukin-2 \[IL-2\] and/or interferon-gamma \[IFN-γ\] and/or tumour necrosis factor-alpha \[TNF-α\] and/or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS) in subjects 60 to 69 years (60-69y) and ≥ 70 years (+70y) old.

Time frame:
At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)
Reported as:
Mean · T-cells/million cells
Frequency of gE-specific CD4 T-cells Expressing at Least Two Different Activation Markers
T-cells/million cellsGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
CD4-All Doubles, Day 0194.47 ± 214.96225.47 ± 370.67201.17 ± 230.96203.70 ± 221.97145.95 ± 164.57
CD4-All Doubles, Month 2459.01 ± 401.25482.84 ± 425.73489.45 ± 423.52173.91 ± 181.86230.28 ± 250.70
CD4-All Double, Month 32246.29 ± 1976.422372.07 ± 1877.432569.29 ± 2052.74670.80 ± 606.93550.11 ± 448.15
SecondaryFrequency of gE-specific CD4 T-cells Expressing IFN-γ and at Least Another Activation Marker

Among other activation markers expressed were interleukin-2 \[IL-2\] or tumour necrosis factor-alpha \[TNF-α\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).

Time frame:
At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)
Reported as:
Mean · T-cells/million cells
Frequency of gE-specific CD4 T-cells Expressing IFN-γ and at Least Another Activation Marker
T-cells/million cellsGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Day 0156.54 ± 199.12169.01 ± 326.34152.28 ± 220.50157.13 ± 180.00118.35 ± 125.08
Month 2279.39 ± 343.61279.20 ± 336.29292.15 ± 345.65124.05 ± 151.42168.34 ± 213.83
Month 31179.29 ± 1021.141296.04 ± 1132.181417.40 ± 1303.60363.23 ± 364.74341.36 ± 313.79
SecondaryFrequency of gE-specific CD4 T-cells Expressing IL-2 and at Least Another Activation Marker

Among other activation markers expressed were interferon-gamma \[IFN-γ\] or tumour necrosis factor-alpha \[TNF-α\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).

Time frame:
At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)
Reported as:
Mean · T-cells/million cells
Frequency of gE-specific CD4 T-cells Expressing IL-2 and at Least Another Activation Marker
T-cells/million cellsGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Day 0171.21 ± 208.49191.28 ± 307.40180.85 ± 193.48172.41 ± 184.32125.22 ± 134.81
Month 2416.12 ± 369.85442.17 ± 363.10438.27 ± 378.81150.47 ± 160.29199.34 ± 224.39
Month 32077.06 ± 1860.402156.40 ± 1697.782315.84 ± 1847.24597.76 ± 531.07491.06 ± 396.39
SecondaryFrequency of gE-specific CD4 T-cells Expressing TNF-α and at Least Another Activation Marker

Among other activation markers expressed were interleukin-2 \[IL-2\] or interferon-gamma \[IFN-γ\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).

Time frame:
At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)
Reported as:
Mean · T-cells//million cells
Frequency of gE-specific CD4 T-cells Expressing TNF-α and at Least Another Activation Marker
T-cells//million cellsGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Day 097.28 ± 137.06121.05 ± 296.79116.91 ± 173.65110.66 ± 162.0281.40 ± 107.44
Month 2251.94 ± 277.71256.15 ± 304.91263.39 ± 284.9695.84 ± 125.15120.73 ± 148.24
Month 31317.39 ± 1304.531282.96 ± 1183.691389.62 ± 1231.76350.23 ± 380.60252.86 ± 253.55
SecondaryFrequency of gE-specific CD4 T-cells Expressing CD40L and at Least Another Activation Marker

Among other activation markers expressed were interleukin-2 \[IL-2\] or interferon-gamma \[IFN-γ\] or tumour necrosis factor-alpha \[TNF-α\] . Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).

Time frame:
At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)
Reported as:
Mean · T-cells/million cells
Frequency of gE-specific CD4 T-cells Expressing CD40L and at Least Another Activation Marker
T-cells/million cellsGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Day 0142.88 ± 169.52153.80 ± 214.95151.37 ± 160.38155.90 ± 187.47111.55 ± 126.92
Month 2385.34 ± 348.25405.95 ± 359.46417.20 ± 361.59132.62 ± 144.06182.82 ± 195.36
Month 32014.37 ± 1849.252154.81 ± 1799.642303.13 ± 1987.94567.33 ± 566.48433.56 ± 391.64
SecondaryFrequency of gE-specific CD8 T-cells Expressing at Least Two Different Activation Markers

Among the activation markers expressed were interleukin-2 \[IL-2\] and/or interferon-gamma \[IFN-γ\] and/or tumour necrosis factor-alpha \[TNF-α\] and/or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).

Time frame:
At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)
Reported as:
Mean · T-cells/million cells
Frequency of gE-specific CD8 T-cells Expressing at Least Two Different Activation Markers
T-cells/million cellsGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
CD8-All Doubles, Day 074.62 ± 118.0298.88 ± 164.52122.37 ± 221.2080.54 ± 121.84108.21 ± 330.11
CD8-All Doubles, Month 285.29 ± 139.32106.23 ± 141.6386.35 ± 168.10120.06 ± 221.2098.97 ± 299.34
CD8-All Doubles, Month 396.43 ± 155.3788.77 ± 140.95117.70 ± 196.09112.99 ± 165.52116.41 ± 450.85
SecondaryFrequency of gE-specific CD8 T-cells Expressing IFN-γ and at Least Another Activation Marker

Among other activation markers expressed were interleukin-2 \[IL-2\] or tumour necrosis factor-alpha \[TNF-α\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).

Time frame:
At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)
Reported as:
Mean · T-cells/million cells
Frequency of gE-specific CD8 T-cells Expressing IFN-γ and at Least Another Activation Marker
T-cells/million cellsGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Day 060.35 ± 97.1275.79 ± 114.55106.39 ± 199.9670.69 ± 121.23123.99 ± 360.75
Month 265.97 ± 111.02106.74 ± 133.1572.58 ± 92.99106.02 ± 184.4095.05 ± 326.45
Month 388.62 ± 136.1376.92 ± 123.7495.01 ± 138.7796.91 ± 161.10125.69 ± 480.05
SecondaryFrequency of gE-specific CD8 T-cells Expressing IL-2 and at Least Another Activation Marker

Among other activation markers expressed were interferon-gamma \[IFN-γ\] or tumour necrosis factor-alpha \[TNF-α\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).

Time frame:
At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)
Reported as:
Mean · T-cells/million cells
Frequency of gE-specific CD8 T-cells Expressing IL-2 and at Least Another Activation Marker
T-cells/million cellsGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Day 081.42 ± 108.6283.13 ± 131.0790.71 ± 140.1863.56 ± 89.1843.03 ± 58.88
Month 261.05 ± 106.3678.18 ± 92.6583.07 ± 186.8882.47 ± 126.0868.98 ± 85.29
Month 369.06 ± 97.1265.08 ± 83.71103.17 ± 179.5782.95 ± 99.4756.42 ± 120.85
SecondaryFrequency of gE-specific CD8 T-cells Expressing TNF-α and at Least Another Activation Marker

Among other activation markers expressed were interleukin-2 \[IL-2\] or interferon-gamma \[IFN-γ\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).

Time frame:
At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)
Reported as:
Mean · T-cells/million cells
Frequency of gE-specific CD8 T-cells Expressing TNF-α and at Least Another Activation Marker
T-cells/million cellsGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Day 074.94 ± 113.0787.33 ± 117.28111.54 ± 204.3681.54 ± 119.17122.68 ± 362.64
Month 271.42 ± 96.4183.01 ± 124.5075.88 ± 129.33111.15 ± 217.08115.82 ± 356.29
Month 386.81 ± 120.3976.75 ± 137.3799.07 ± 139.42106.97 ± 167.59136.22 ± 470.58
SecondaryFrequency of gE-specific CD8 T-cells Expressing CD40L and at Least Another Activation Marker

Among other activation markers expressed were interleukin-2 \[IL-2\] or interferon-gamma \[IFN-γ\] or tumour necrosis factor-alpha \[TNF-α\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS).

Time frame:
At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)
Reported as:
Mean · T-cells/million cells
Frequency of gE-specific CD8 T-cells Expressing CD40L and at Least Another Activation Marker
T-cells/million cellsGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Day 041.35 ± 54.4861.30 ± 118.4356.85 ± 78.3135.96 ± 69.5159.94 ± 75.13
Month 263.87 ± 82.0266.76 ± 90.2947.20 ± 64.5471.20 ± 93.1854.63 ± 69.92
Month 369.50 ± 105.3665.34 ± 64.1785.57 ± 105.3476.19 ± 72.4433.12 ± 47.32
SecondaryAnti-gE Specific Antibody Concentrations

Concentrations were presented as geometric mean concentrations (GMCs) and expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).

Time frame:
At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)
Reported as:
Geometric mean · EL.U/mL
Anti-gE Specific Antibody Concentrations
EL.U/mLGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Anti-gE, Day 0351.6 (306.2 to 403.8)312.8 (268.1 to 365.0)416.1 (355.0 to 487.7)337.2 (285.8 to 397.7)323.7 (245.2 to 427.3)
Anti-gE, Month 23667.6 (3158.6 to 4258.7)4139.4 (3443.8 to 4975.4)5485.6 (4657.2 to 6461.3)361.5 (304.6 to 429.0)2148.9 (1461.8 to 3158.9)
Anti-gE, Month 39315.3 (8283.2 to 10476.1)12898.0 (11681.2 to 14241.6)15626.5 (14030.3 to 17404.3)6287.2 (5372.0 to 7358.3)4298.3 (3220.0 to 5737.7)
SecondaryAnti-varicella Zoster Virus (VZV) Specific Antibody Concentrations

Concentrations were presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL), as assessed by ELISA.

Time frame:
At pre-vaccination (Day 0), one month after the first vaccination (Month 2) and second vaccination (Month 3)
Reported as:
Geometric mean · mIU/mL
Anti-varicella Zoster Virus (VZV) Specific Antibody Concentrations
mIU/mLGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Anti-VZV, Day 01334.9 (1181.9 to 1507.7)1212.0 (1063.9 to 1380.7)1510.7 (1336.4 to 1707.7)1356.3 (1184.9 to 1552.6)1422.5 (1153.4 to 1754.5)
Anti-VZV, Month 24408.1 (3847.7 to 5050.1)5131.9 (4469.8 to 5892.0)6511.7 (5723.1 to 7409.0)1341.6 (1177.7 to 1528.3)3481.2 (2756.0 to 4397.3)
Anti-VZV, Month 38821.6 (7959.3 to 9777.4)11451.0 (10507.9 to 12478.7)14143.5 (12876.9 to 15534.7)6432.2 (5591.8 to 7398.9)5357.6 (4297.3 to 6679.4)
SecondaryFrequency of gE-specific CD4/CD8 T-cells Expressing at Least Two Different Activation Markers

Among the activation markers expressed were interleukin-2 \[IL-2\] and/or interferon-gamma \[IFN-γ\] and/or tumour necrosis factor-alpha \[TNF-α\] and/or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS). Month 12, 24 and 36 CMI analyses on CD8+ T cells were not performed as no detectable CD8 T+ cell response was measured to any of the vaccine formulations in the primary (108494) study.

Time frame:
At Months 12, 24 and 36
Reported as:
Mean · T-cells/million cells
Frequency of gE-specific CD4/CD8 T-cells Expressing at Least Two Different Activation Markers
T-cells/million cellsGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
CD4-All Doubles, Month 121135.8 ± 936.01275.5 ± 1195.41274.0 ± 995.0340.4 ± 296.8274.5 ± 217.3
CD4-All Doubles, Month 241004.1 ± 838.81195.5 ± 1375.51079.9 ± 948.0244.1 ± 233.2285.2 ± 255.6
CD4-All Doubles, Month 36827.3 ± 922.9969.7 ± 1034.9896.3 ± 770.4239.7 ± 181.7229.7 ± 217.1
SecondaryFrequency of gE-specific CD4/CD8 T-cells Expressing IFN-γ and at Least Another Activation Marker

Among other activation markers expressed were interleukin-2 \[IL-2\] or tumour necrosis factor-alpha \[TNF-α\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS). Month 12, 24 and 36 CMI analyses on CD8+ T cells were not performed as no detectable CD8 T+ cell response was measured to any of the vaccine formulations in the primary (108494) study.

Time frame:
At Months 12, 24 and 36
Reported as:
Mean · T-cells/million cells
Frequency of gE-specific CD4/CD8 T-cells Expressing IFN-γ and at Least Another Activation Marker
T-cells/million cellsGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Month 12659.9 ± 594.3767.8 ± 895.1718.9 ± 634.2235.5 ± 244.7176.8 ± 152.7
Month 24541.9 ± 503.1668.9 ± 1140.6543.6 ± 554.7157.0 ± 183.4181.2 ± 158.4
Month 36491.8 ± 604.1583.3 ± 819.0492.3 ± 437.0172.2 ± 155.1162.0 ± 151.4
SecondaryFrequency of gE-specific CD4/CD8 T-cells Expressing IL-2 and at Least Another Activation Marker

Among other activation markers expressed were interferon-gamma \[IFN-γ\] or tumour necrosis factor-alpha \[TNF-α\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS). Month 12, 24 and 36 CMI analyses on CD8+ T cells were not performed as no detectable CD8 T+ cell response was measured to any of the vaccine formulations in the primary (108494) study.

Time frame:
At Months 12, 24 and 36
Reported as:
Mean · T-cells/million cells
Frequency of gE-specific CD4/CD8 T-cells Expressing IL-2 and at Least Another Activation Marker
T-cells/million cellsGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Month 121056.2 ± 901.01164.7 ± 1029.11168.3 ± 935.4291.7 ± 266.6243.9 ± 204.8
Month 24943.0 ± 809.51100.2 ± 1158.91007.8 ± 909.5213.0 ± 207.4233.0 ± 244.5
Month 36768.9 ± 871.5890.2 ± 883.3834.7 ± 743.9205.8 ± 154.5213.9 ± 202.2
SecondaryFrequency of gE-specific CD4/CD8 T-cells Expressing TNFα and at Least Another Activation Marker

Among other activation markers expressed were interleukin-2 \[IL-2\] or interferon-gamma \[IFN-γ\] or cluster of differentiation 40-ligand \[CD40-L\]. Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS). Month 12, 24 and 36 CMI analyses on CD8+ T cells were not performed as no detectable CD8 T+ cell response was measured to any of the vaccine formulations in the primary (108494) study.

Time frame:
At Month 12, 24 and 36
Reported as:
Geometric mean · T-cells/million cells
Frequency of gE-specific CD4/CD8 T-cells Expressing TNFα and at Least Another Activation Marker
T-cells/million cellsGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Month 12673.7 ± 616.0736.2 ± 878.5736.7 ± 660.7193.2 ± 239.4136.0 ± 132.8
Month 24567.9 ± 527.7663.1 ± 1097.0591.5 ± 586.6144.1 ± 196.1133.0 ± 158.1
Month 36497.4 ± 652.5567.9 ± 808.4510.7 ± 522.1117.9 ± 151.798.1 ± 116.0
SecondaryFrequency of gE-specific CD4/CD8 T-cells Expressing CD40L and at Least Another Activation Marker

Among other activation markers expressed were interleukin-2 \[IL-2\] or interferon-gamma \[IFN-γ\] or tumour necrosis factor-alpha \[TNF-α\] . Analysis of cytokines expression was done by means of in vitro flow cytometry using intracellular cytokine staining (ICS). Month 12, 24 and 36 CMI analyses on CD8+ T cells were not performed as no detectable CD8 T+ cell response was measured to any of the vaccine formulations in the primary (108494) study.

Time frame:
At Month 12, 24 and 36
Reported as:
Mean · T-cells/million cells
Frequency of gE-specific CD4/CD8 T-cells Expressing CD40L and at Least Another Activation Marker
T-cells/million cellsGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Month 12969.0 ± 811.81057.2 ± 943.41062.8 ± 850.3267.5 ± 246.0221.0 ± 180.9
Month 24935.2 ± 801.51079.9 ± 1040.1981.6 ± 890.9210.8 ± 187.2270.3 ± 248.6
Month 36753.0 ± 852.9912.9 ± 1009.2823.0 ± 727.9202.5 ± 166.3202.8 ± 187.1
SecondaryAnti-gE Specific Antibody Concentrations

Concentrations were presented as geometric mean concentrations (GMCs) and expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).

Time frame:
At Months 12, 24 and 36
Reported as:
Geometric mean · EL.U/mL
Anti-gE Specific Antibody Concentrations
EL.U/mLGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Anti-gE, Month 123384.8 (2987.2 to 3835.4)4280.3 (3818.4 to 4798.0)5258.2 (4725.2 to 5851.3)1664.5 (1443.7 to 1919.1)1888.2 (1452.7 to 2454.1)
Anti-gE, Month 242363.8 (2081.0 to 2685.0)2784.6 (2494.0 to 3109.1)3390.0 (3013.6 to 3813.5)1126.3 (982.2 to 1291.6)1339.1 (1038.3 to 1727.0)
Anti-gE, Month 362064.1 (1834.6 to 2322.3)2444.3 (2175.2 to 2746.8)2956.4 (2653.6 to 3293.7)959.5 (831.0 to 1107.9)973.9 (755.4 to 1255.6)
SecondaryAnti-varicella Zoster Virus (VZV) Specific Antibody Concentrations

Concentrations were presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL).

Time frame:
At Months 12, 24 and 36
Reported as:
Geometric mean · mIU/mL
Anti-varicella Zoster Virus (VZV) Specific Antibody Concentrations
mIU/mLGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Anti-VZV, Month 124190.1 (3845.4 to 4565.8)4761.3 (4367.0 to 5191.3)5559.1 (5141.5 to 6010.7)2704.1 (2424.5 to 3016.0)2733.8 (2208.8 to 3383.7)
Anti-VZV, Month 242557.4 (2397.5 to 2727.8)2673.6 (2523.8 to 2832.3)2976.0 (2819.5 to 3141.3)1849.3 (1701.8 to 2009.5)1922.6 (1643.1 to 2249.6)
Anti-VZV, Month 362426.6 (2257.2 to 2608.8)2555.0 (2385.8 to 2736.3)2826.7 (2648.4 to 3017.0)1729.9 (1582.5 to 1891.1)1739.9 (1481.0 to 2044.0)
SecondaryFrequency of VZV-specific Memory B-cells in a Subset of Subjects

Memory B cells specific to the gE antigen, as assessed by the enzyme-linked immunosorbent spot (ELISPOT) method, were expressed as a frequency of the specific memory B-cells per million memory B-cells. Results were tabulated for subjects aged 70 years and older.

Time frame:
At pre-vaccination (Day 0) and at Month 3
Reported as:
Mean · B-cells/million cells
Frequency of VZV-specific Memory B-cells in a Subset of Subjects
B-cells/million cellsGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Memory B-cells, Day 0336.5 ± 359.5490.4 ± 704.7356.6 ± 348.0332.3 ± 404.9380.6 ± 299.7
Memory B-cells, Month 35699.3 ± 8166.25997.1 ± 5034.69707.5 ± 8787.11583.7 ± 2266.01042.2 ± 1139.9
SecondaryNumber of Subjects With Different Biochemical and Haematological Levels

Among biochemical and haematological parameters assessed were albumin \[ALB\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], basophils \[BAS\], calcium \[CAL\], eosinophils \[EOS\], fibrinogen \[FIB\], haematocrit \[HEM\], hemoglobin \[Hgb\], leucocytes \[LEU\], lymphocytes \[LYM\], lactate dehydrogenate \[LDH\], monocytes \[MON\], neutrophils \[NEU\], partial thromboplastin time \[PTPT\], platelets \[PLA\], pro thrombin time \[PTT\], red blood cells \[RBC\], serum creatinine \[SCREA\], total protein \[TP\]. Levels of haematological/biochemical parameters assessed in terms of normal laboratory values were - unknown, below, within and above.

Time frame:
At Day 0, Month 2 and Month 3
Reported as:
Count of participants · Participants
Number of Subjects With Different Biochemical and Haematological Levels
ParticipantsGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
ALB, Day 0 — Unknown00000
ALB, Day 0 — Below131214124
ALB, Day 0 — Within5764596119
ALB, Day 0 — Above41221
ALB, Month 2 — Unknown00000
ALB, Month 2 — Below131411176
ALB, Month 2 — Within5761625516
ALB, Month 2 — Above22130
ALB, Month 3 — Unknown00100
ALB, Month 3 — Below8129174
ALB, Month 3 — Within6162615517
ALB, Month 3 — Above13230
ALT, Day 0 — Unknown00001
ALT, Day 0 — Below12010
ALT, Day 0 — Within15015115215450
ALT, Day 0 — Above131312103
ALT, Month 2 — Unknown00000
ALT, Month 2 — Below11010
ALT, Month 2 — Within15214915515048
ALT, Month 2 — Above9147133
ALT, Month 3 — Unknown00100
ALT, Month 3 — Below12010
ALT, Month 3 — Within15215015415046
ALT, Month 3 — Above7126135
AST, Day 0 — Unknown00000
AST, Day 0 — Below01130
AST, Day 0 — Within15615415614851
AST, Day 0 — Above8117143
AST, Month 2 — Unknown00000
AST, Month 2 — Below01000
AST, Month 2 — Within15015115115151
AST, Month 2 — Above121211130
AST, Month 3 — Unknown00200
AST, Month 3 — Below03000
AST, Month 3 — Within15114615315348
AST, Month 3 — Above9156113
BAS, Day 0 — Unknown711561
BAS, Day 0 — Below01001
BAS, Day 0 — Within14814715315350
BAS, Day 0 — Above97662
BAS, Month 2 — Unknown00100
BAS, Month 2 — Below01111
BAS, Month 2 — Within15315515215447
BAS, Month 2 — Above98893
BAS, Month 3 — Unknown00000
BAS, Month 3 — Below00201
BAS, Month 3 — Within15015114715548
BAS, Month 3 — Above10131292
CAL, Day 0 — Unknown00000
CAL, Day 0 — Below31230
CAL, Day 0 — Within7076727123
CAL, Day 0 — Above10111
CAL, Month 2 — Unknown00000
CAL, Month 2 — Below41530
CAL, Month 2 — Within6875687122
CAL, Month 2 — Above01110
CAL, Month 3 — Unknown00100
CAL, Month 3 — Below51250
CAL, Month 3 — Within6476706921
CAL, Month 3 — Above10010
EOS, Day 0 — Unknown811561
EOS, Day 0 — Below131112102
EOS, Day 0 — Within13012713513747
EOS, Day 0 — Above131712124
EOS, Month 2 — Unknown00100
EOS, Month 2 — Below11815103
EOS, Month 2 — Within14013812814243
EOS, Month 2 — Above111818125
EOS, Month 3 — Unknown10000
EOS, Month 3 — Below1091282
EOS, Month 3 — Within12714412613445
EOS, Month 3 — Above221123224
FIB, Day 0 — Unknown14410
FIB, Day 0 — Below00000
FIB, Day 0 — Within3634363910
FIB, Day 0 — Above3739353514
FIB, Month 2 — Unknown01210
FIB, Month 2 — Below00010
FIB, Month 2 — Within4035373512
FIB, Month 2 — Above3241353810
FIB, Month 3 — Unknown01100
FIB, Month 3 — Below00010
FIB, Month 3 — Within403640399
FIB, Month 3 — Above3040323512
HEM, Day 0 — Unknown14000
HEM, Day 0 — Below211627204
HEM, Day 0 — Within14114312913750
HEM, Day 0 — Above13880
HEM, Month 2 — Unknown00100
HEM, Month 2 — Below271925284
HEM, Month 2 — Within13314413113246
HEM, Month 2 — Above21541
HEM, Month 3 — Unknown00010
HEM, Month 3 — Below302325256
HEM, Month 3 — Within12813713413245
HEM, Month 3 — Above24260
HgB, Day 0 — Unknown14000
HgB, Day 0 — Below231419228
HgB, Day 0 — Within13814214213746
HgB, Day 0 — Above26360
HgB, Month 2 — Unknown00100
HgB, Month 2 — Below262226266
HgB, Month 2 — Within13414013413445
HgB, Month 2 — Above22140
HgB, Month 3 — Unknown00010
HgB, Month 3 — Below272126247
HgB, Month 3 — Within13114113313644
HgB, Month 3 — Above22230
LEU, Day 0 — Unknown14000
LEU, Day 0 — Below35261
LEU, Day 0 — Within15314715315352
LEU, Day 0 — Above710961
LEU, Month 2 — Unknown00100
LEU, Month 2 — Below37360
LEU, Month 2 — Within15214815314746
LEU, Month 2 — Above795115
LEU, Month 3 — Unknown00000
LEU, Month 3 — Below28560
LEU, Month 3 — Within15015014915050
LEU, Month 3 — Above86781
LYM, Day 0 — Unknown711561
LYM, Day 0 — Below181324175
LYM, Day 0 — Within13714013013744
LYM, Day 0 — Above22554
LYM, Month 2 — Unknown00100
LYM, Month 2 — Below151823157
LYM, Month 2 — Within14414413114742
LYM, Month 2 — Above32722
LYM, Month 3 — Unknown00000
LYM, Month 3 — Below12819207
LYM, Month 3 — Within14415413814242
LYM, Month 3 — Above42422
LDH, Day 0 — Unknown11000
LDH, Day 0 — Below00000
LDH, Day 0 — Within6868667024
LDH, Day 0 — Above58950
LDH, Month 2 — Unknown00000
LDH, Month 2 — Below00000
LDH, Month 2 — Within6465647021
LDH, Month 2 — Above8121051
LDH, Month 3 — Unknown00100
LDH, Month 3 — Below00000
LDH, Month 3 — Within6363666820
LDH, Month 3 — Above714671
MON, Day 0 — Unknown711561
MON, Day 0 — Below14101
MON, Day 0 — Within14814214714849
MON, Day 0 — Above8911113
MON, Month 2 — Unknown00100
MON, Month 2 — Below00200
MON, Month 2 — Within15315514614548
MON, Month 2 — Above9913193
MON, Month 3 — Unknown00000
MON, Month 3 — Below21130
MON, Month 3 — Within14515114514849
MON, Month 3 — Above131215132
NEU, Day 0 — Unknown811561
NEU, Day 0 — Below32333
NEU, Day 0 — Within14514114714648
NEU, Day 0 — Above8129102
NEU, Month 2 — Unknown10100
NEU, Month 2 — Below25461
NEU, Month 2 — Within15015214415147
NEU, Month 2 — Above971373
NEU, Month 3 — Unknown10000
NEU, Month 3 — Below73762
NEU, Month 3 — Within14615714514946
NEU, Month 3 — Above64993
PTPT, Day 0 — Unknown34300
PTPT, Day 0 — Below52230
PTPT, Day 0 — Within4242424311
PTPT, Day 0 — Above37655
PTPT, Month 2 — Unknown01310
PTPT, Month 2 — Below74630
PTPT, Month 2 — Within5958576420
PTPT, Month 2 — Above611662
PTPT, Month 3 — Unknown00100
PTPT, Month 3 — Below44651
PTPT, Month 3 — Within6261596218
PTPT, Month 3 — Above412782
PLA, Day 0 — Unknown14000
PLA, Day 0 — Below649102
PLA, Day 0 — Within14715014914849
PLA, Day 0 — Above108673
PLA, Month 2 — Unknown00100
PLA, Month 2 — Below6711121
PLA, Month 2 — Within15015214514549
PLA, Month 2 — Above65571
PLA, Month 3 — Unknown00010
PLA, Month 3 — Below669123
PLA, Month 3 — Within14915314714846
PLA, Month 3 — Above55532
PTT, Day 0 — Unknown33300
PTT, Day 0 — Below49555
PTT, Day 0 — Within4438424411
PTT, Day 0 — Above25320
PTT, Month 2 — Unknown01310
PTT, Month 2 — Below510673
PTT, Month 2 — Within6562616519
PTT, Month 2 — Above21210
PTT, Month 3 — Unknown00100
PTT, Month 3 — Below510682
PTT, Month 3 — Within6264636419
PTT, Month 3 — Above33330
RBC, Day 0 — Unknown15210
RBC, Day 0 — Below232125239
RBC, Day 0 — Within13713512813642
RBC, Day 0 — Above35953
RBC, Month 2 — Unknown01100
RBC, Month 2 — Below252327248
RBC, Month 2 — Within13613812813542
RBC, Month 2 — Above12651
RBC, Month 3 — Unknown10010
RBC, Month 3 — Below272326235
RBC, Month 3 — Within12913813113646
RBC, Month 3 — Above33440
SCREA, Day 0 — Unknown11100
SCREA, Day 0 — Below42330
SCREA, Day 0 — Within13013212813543
SCREA, Day 0 — Above2931322711
SCREA, Month 2 — Unknown00000
SCREA, Month 2 — Below32132
SCREA, Month 2 — Within13513112913138
SCREA, Month 2 — Above2431323011
SCREA, Month 3 — Unknown00100
SCREA, Month 3 — Below33220
SCREA, Month 3 — Within13212713013442
SCREA, Month 3 — Above253428289
TP, Day 0 — Unknown00000
TP, Day 0 — Below62931
TP, Day 0 — Within6875667223
TP, Day 0 — Above00000
TP, Month 2 — Unknown00000
TP, Month 2 — Below62942
TP, Month 2 — Within6675657120
TP, Month 2 — Above00000
TP, Month 3 — Unknown00100
TP, Month 3 — Below371360
TP, Month 3 — Within6770586921
TP, Month 3 — Above00100
SecondaryNumber of German Subjects With Different Biochemical and Haematological Levels

Among biochemical and haematological parameters assessed were albumin \[ALB\], calcium \[CAL\], fibrinogen \[FIB\], lactate dehydrogenase \[LDH\], partial thrombo-plastin time \[PTPT\], pro thrombin time \[PTT\], total protein \[TP\]. Levels of haematological/biochemical parameters assessed in terms of normal laboratory values were - below, within, above and missing, as compared to the pre-vaccination status (below, within, above or missing). Values for electrophoresis (globulins and albumin/globulin ratio) were not displayed.

Time frame:
At one week post-vaccination 1 (Month 0)
Reported as:
Count of participants · Participants
Number of German Subjects With Different Biochemical and Haematological Levels
ParticipantsGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
ALB - Below — Below871072
ALB - Below — Within00000
ALB - Below — Above00000
ALB - Below — Missing00000
ALB - Within — Below35242
ALB - Within — Within121212124
ALB - Within — Above00000
ALB - Within — Missing10010
CAL - Below — Below11———
CAL - Below — Within10———
CAL - Below — Above00———
CAL - Below — Missing00———
CAL - Within — Below10100
CAL - Within — Within192321228
CAL - Within — Above00210
CAL - Within — Missing10010
CAL - Above — Below0————
CAL - Above — Within1————
CAL - Above — Above0————
CAL - Above — Missing0————
FIB - Within — Below00000
FIB - Within — Within958134
FIB - Within — Above68431
FIB - Within — Missing00000
FIB - Above — Below00000
FIB - Above — Within00230
FIB - Above — Above8111043
FIB - Above — Missing10010
LDH- Within — Below00000
LDH- Within — Within181919228
LDH- Within — Above20100
LDH- Within — Missing10010
LDH- Above — Below0000—
LDH- Above — Within1311—
LDH- Above — Above1230—
LDH- Above — Missing0000—
LDH- Missing — Below0————
LDH- Missing — Within0————
LDH- Missing — Above1————
LDH- Missing — Missing0————
PTPT - Missing — Below00000
PTPT - Missing — Within00000
PTPT - Missing — Above00000
PTPT - Missing — Missing222423248
PTT - Missing — Below00000
PTT - Missing — Within00000
PTT - Missing — Above00100
PTT - Missing — Missing222422248
TP - Below — Below0—0——
TP - Below — Within2—1——
TP - Below — Above0—0——
TP - Below — Missing0—0——
TP - Within — Below00210
TP - Within — Within212421228
TP - Within — Above00000
TP - Within — Missing10010
SecondaryNumber of German Subjects With Different Biochemical and Haematological Levels

Among biochemical and haematological parameters assessed were albumin \[ALB\], calcium \[CAL\], fibrinogen \[FIB\], lactate dehydrogenase \[LDH\], partial thrombo-plastin time \[PTPT\], pro thrombin time \[PTT\], total protein \[TP\]. Levels of haematological/biochemical parameters assessed in terms of normal laboratory values were - below, within, above and missing, as compared to the pre-vaccination status (below, within, above or missing). Values for electrophoresis (globulins and albumin/globulin ratio) were not displayed.

Time frame:
At one week post-vaccination 2 (Month 2)
Reported as:
Count of participants · Participants
Number of German Subjects With Different Biochemical and Haematological Levels
ParticipantsGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
ALB - Below — Below46862
ALB - Below — Within11100
ALB - Below — Above00000
ALB - Below — Missing30110
ALB - Within — Below22241
ALB - Within — Within121511125
ALB - Within — Above00000
ALB - Within — Missing20110
CAL - Below — Below10———
CAL - Below — Within01———
CAL - Below — Above00———
CAL - Below — Missing10———
CAL - Within — Below00200
CAL - Within — Within162320228
CAL - Within — Above10000
CAL - Within — Missing40220
CAL - Above — Below0————
CAL - Above — Within1————
CAL - Above — Above0————
CAL - Above — Missing0————
FIB - Within — Below00000
FIB - Within — Within886114
FIB - Within — Above55531
FIB - Within — Missing20120
FIB - Above — Below00000
FIB - Above — Within01310
FIB - Above — Above610873
FIB - Above — Missing30100
LDH - Within — Below00000
LDH - Within — Within141615208
LDH - Within — Above23310
LDH - Within — Missing50220
LDH - Above — Below0000—
LDH - Above — Within0411—
LDH - Above — Above2130—
LDH - Above — Missing0000—
LDH - Missing — Below0————
LDH - Missing — Within1————
LDH - Missing — Above0————
LDH - Missing — Missing0————
PTPT - Missing — Below01210
PTPT - Missing — Within182220198
PTPT - Missing — Above11020
PTPT - Missing — Missing30120
PTT - Missing — Below11020
PTT - Missing — Within182322208
PTT - Missing — Above00000
PTT - Missing — Missing30120
TP - Below — Below0—0——
TP - Below — Within0—1——
TP - Below — Above0—0——
TP - Below — Missing2—0——
TP - Within — Below00220
TP - Within — Within192419208
TP - Within — Above00000
TP - Within — Missing30220
SecondaryNumber of Subjects With Any and Grade 3 Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

Time frame:
During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Reported as:
Count of participants · Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
ParticipantsGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Any Pain, Dose 194119927
Grade 3 Pain, Dose 100300
Any Redness, Dose 140494312
Grade 3 Redness, Dose 122300
Any Swelling, Dose 126212431
Grade 3 Swelling, Dose 112200
Any Pain, Dose 2999399934
Grade 3 Pain, Dose 243330
Any Redness, Dose 2515452482
Grade 3 Redness, Dose 213220
Any Swelling, Dose 2302330270
Grade 3 Swelling, Dose 200100
Any Pain, Across doses11512122939
Grade 3 Pain, Across doses43630
Any Redness, Across doses686668492
Grade 3 Redness, Across doses25420
Any Swelling, Across doses443345301
Grade 3 Swelling, Across doses12200
SecondaryNumber of Subjects With Any, Grade 3 and Related Solicited General Symptoms

Assessed solicited general symptoms were arthralgia, fatigue, fever \[defined as oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)\], headache and myalgia. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

Time frame:
During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
ParticipantsGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Any Fatigue, Dose 1364846208
Grade 3 Fatigue, Dose 112221
Related Fatigue, Dose 1303434126
Any Fever, Dose 177540
Grade 3 Fever, Dose 100000
Related Fever, Dose 175340
Any Headache, Dose 1232524137
Grade 3 Headache, Dose 100200
Related Headache, Dose 119171366
Any Myalgia, Dose 1485746118
Grade 3 Myalgia, Dose 112210
Related Myalgia, Dose 1415241106
Any Fatigue, Dose 2567052389
Grade 3 Fatigue, Dose 226410
Related Fatigue, Dose 2474843277
Any Fever, Dose 213131850
Grade 3 Fever, Dose 201000
Related Fever, Dose 212121850
Any Headache, Dose 2394739277
Grade 3 Headache, Dose 223200
Related Headache, Dose 2323235215
Any Myalgia, Dose 2597159465
Grade 3 Myalgia, Dose 247420
Related Myalgia, Dose 2526157414
Any Fatigue, Across doses698573471
Grade 3 Fatigue, Across doses37631
Related Fatigue, Across doses576059339
Any Fever, Across doses19182290
Grade 3 Fever, Across doses01000
Related Fever, Across doses18152090
Any Headache, Across doses475951369
Grade 3 Headache, Across doses23400
Related Headache, Across doses394142257
Any Myalgia, Across doses748970499
Grade 3 Myalgia, Across doses58630
Related Myalgia, Across doses668067467
SecondaryNumber of Subjects With Occurrence of Clinically Diagnosed Herpes Zoster (HZ) Episodes

Clinically diagnosed episodes included rash that was assessed by hives, idiopathic thrombocytopenic purpura, petechiae.

Time frame:
From Month 0 to Month 3
Reported as:
Count of participants · Participants
Number of Subjects With Occurrence of Clinically Diagnosed Herpes Zoster (HZ) Episodes
ParticipantsGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Number of Subjects With Occurrence of Clinically Diagnosed Herpes Zoster (HZ) Episodes10000
SecondaryNumber of Subjects With Occurrence of Clinically Diagnosed HZ Episodes

Clinically diagnosed episodes included rash that was assessed by hives, idiopathic thrombocytopenic purpura, petechiae.

Time frame:
From Month 3 up to Month 36
Reported as:
Count of participants · Participants
Number of Subjects With Occurrence of Clinically Diagnosed HZ Episodes
ParticipantsGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Month 3 - Month 1200010
Month 12 - Month 2410000
Month 24 - Month 3600001
SecondaryNumber of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

Time frame:
During the 30-day (Days 0-29) post-vaccination period
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
ParticipantsGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Any AE(s)5552544116
Grade 3 AE(s)7101054
Related AE(s)202224132
SecondaryNumber of Subjects With Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
From Month 0 to Month 3
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs)
ParticipantsGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Number of Subjects With Serious Adverse Events (SAEs)24363
SecondaryNumber of Subjects With Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
From Month 3 to Month 12
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs)
ParticipantsGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED Group
Month 3 - Month 12111411163
Month 12 - Month 242127292511
Month 24 - Month 36191225205

Adverse events

Collected over Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: during the 30-day (Days 0-29) post-vaccination period; SAEs: during the entire study period (from Day 0 to Month 36).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK1437173A _LD Group2/164 (1.2%)53/164 (32.3%)134/164 (81.7%)
GSK1437173A _MD Group3/166 (1.8%)57/166 (34.3%)142/166 (85.5%)
GSK1437173A _HD Group3/165 (1.8%)68/165 (41.2%)140/165 (84.8%)
Placebo + GSK1437173A _HD Group5/165 (3%)67/165 (40.6%)124/165 (75.2%)
Placebo Group1/54 (1.9%)22/54 (40.7%)19/54 (35.2%)
Most frequent serious events
Showing 10 of 204
Most frequent serious events
EventGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupPlacebo Group
BradyarrhythmiaCardiac disorders0/1640/1660/1650/1653/54
Cardiac failureCardiac disorders3/1642/1661/1651/1652/54
ArthralgiaMusculoskeletal and connective tissue disorders0/1640/1660/1650/1652/54
OsteoarthritisMusculoskeletal and connective tissue disorders2/1641/1665/1653/1651/54
Angina pectorisCardiac disorders0/1642/1664/1653/1650/54
Transient ischaemic attackNervous system disorders3/1640/1661/1654/1650/54
Microcytic anaemiaBlood and lymphatic system disorders0/1640/1660/1650/1651/54
Acute myocardial infarctionCardiac disorders0/1640/1661/1650/1651/54
Atrial fibrillationCardiac disorders0/1642/1660/1653/1651/54
Atrial flutterCardiac disorders0/1640/1660/1650/1651/54
Most frequent other events
Most frequent other events
EventGSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupPlacebo Group
PainGeneral disorders115/164121/166122/16593/1659/54
MyalgiaMusculoskeletal and connective tissue disorders75/16489/16670/16549/1659/54
FatigueGeneral disorders69/16485/16673/16547/16512/54
ErythemaSkin and subcutaneous tissue disorders68/16465/16668/16550/1652/54
HeadacheNervous system disorders48/16460/16651/16536/1659/54
SwellingGeneral disorders43/16432/16645/16530/1651/54
PyrexiaGeneral disorders20/16419/16622/1659/1650/54

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED GROUPTotal
Mean72.8 ± 5.572.9 ± 5.173.0 ± 5.773.1 ± 5.972.1 ± 5.272.9 ± 5.5
Sex: Female, Male
Sex: Female, Male(Participants)GSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED GROUPTotal
Female88100859536404
Male7666807018310
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GSK1437173A _LD GroupGSK1437173A _MD GroupGSK1437173A _HD GroupPlacebo + GSK1437173A _HD GroupGSK1437173A_MODIFIED GROUPTotal
Geographic ancestry — African Heritage/African American010001
Geographic ancestry — Asian - Central/South Asian Heritage010001
Geographic ancestry — White - Arabic/North African Heritage111003
Geographic ancestry — White - Caucasian/European Heritage16216316416554708
Geographic ancestry — Other100001
08

Study locations

11 sites
  • GSK Investigational Site
    Hradec Kralove, 500 01, Czechia
  • GSK Investigational Site
    Mannheim, Baden-Wuerttemberg 68161, Germany
  • GSK Investigational Site
    Wuerzburg, Bayern 97070, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30625, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45359, Germany
  • GSK Investigational Site
    Koeln, Nordrhein-Westfalen 51069, Germany
  • GSK Investigational Site
    Berlin, 13347, Germany
  • GSK Investigational Site
    Amsterdam, 1018 WT, Netherlands
  • GSK Investigational Site
    Rotterdam, 3011 EN, Netherlands
  • GSK Investigational Site
    Eskilstuna, SE-631 88, Sweden
  • GSK Investigational Site
    Uppsala, SE-751 85, Sweden
09

References and documents

Publications

  • Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JA, Richardus JH, Plassmann G, Schwarz TF, Ledent E, Heineman TC. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014 Mar 26;32(15):1745-53. doi: 10.1016/j.vaccine.2014.01.019. Epub 2014 Feb 6. PubMed 24508036 ↗
  • Schwarz TF, Volpe S, Catteau G, Chlibek R, David MP, Richardus JH, Lal H, Oostvogels L, Pauksens K, Ravault S, Rombo L, Sonder G, Smetana J, Heineman T, Bastidas A. Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults. Hum Vaccin Immunother. 2018 Jun 3;14(6):1370-1377. doi: 10.1080/21645515.2018.1442162. Epub 2018 Mar 21. PubMed 29461919 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2007 to primary completion in Oct 2007, 7 months.

Results were first posted in Jan 2019, 11 years 3 months after primary completion. A results delay was requested in Mar 2012.

Of 22 phase 2 interventional studies under Herpes Zoster, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 27. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2007
First posted
Feb 13, 2007
StartActual
Feb 14, 2007
Primary completionActual
Oct 4, 2007
CompletionActual
Jul 14, 2010
Results delay requested
Mar 9, 2012
Results first posted
Jan 8, 2019
Last update
Mar 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00434577
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 13, 2007
Start date
Feb 14, 2007
Primary completion
Oct 4, 2007
Completion
Jul 14, 2010
Results posted
Jan 8, 2019
Last update
Mar 15, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion